111 related articles for article (PubMed ID: 37085990)
21. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
22. CD8 + T-cell Density Is an Independent Predictor of Survival and Response to Adjuvant Chemotherapy in Stage III Colon Cancer.
Garcia P; Hartman D; Choudry H; Pai RK
Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):69-76. PubMed ID: 36508180
[TBL] [Abstract][Full Text] [Related]
23. The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.
Chu-Yuan H; Jing P; Yi-Sheng W; He-Ping P; Hui Y; Chu-Xiong Z; Guo-Jian L; Guo-Qiang W
BMC Cancer; 2013 Apr; 13():177. PubMed ID: 23551939
[TBL] [Abstract][Full Text] [Related]
24. High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer.
Hanke T; Melling N; Simon R; Sauter G; Bokemeyer C; Lebok P; Terracciano LM; Izbicki JR; Marx AH
Int J Clin Exp Pathol; 2015; 8(7):8227-35. PubMed ID: 26339391
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.
Yoon HH; Orrock JM; Foster NR; Sargent DJ; Smyrk TC; Sinicrope FA
PLoS One; 2012; 7(8):e42274. PubMed ID: 22879926
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
28. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological Features Combined With Immune Infiltration Could Well Distinguish Outcomes in Stage II and Stage III Colorectal Cancer: A Retrospective Study.
Ren J; Xu L; Zhou S; Ouyang J; You W; Sheng N; Yan L; Peng D; Xie L; Wang Z
Front Oncol; 2021; 11():776997. PubMed ID: 34926285
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
31. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
[TBL] [Abstract][Full Text] [Related]
33. A nomogram based on collagen signature for predicting the immunoscore in colorectal cancer.
Jiang W; Yu X; Dong X; Long C; Chen D; Cheng J; Yan B; Xu S; Lin Z; Chen G; Zhuo S; Yan J
Front Immunol; 2023; 14():1269700. PubMed ID: 37781377
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
[TBL] [Abstract][Full Text] [Related]
35. Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy.
Yun S; Koh J; Nam SK; Kwak Y; Ahn SH; Do Park J; Kim HH; Kim WH; Lee HS
Cancer Immunol Immunother; 2021 Feb; 70(2):431-441. PubMed ID: 32785776
[TBL] [Abstract][Full Text] [Related]
36. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer.
Wang F; Lu S; Cao D; Qian J; Li C; Zhang R; Wang F; Wu M; Liu Y; Pan Z; Wu X; Lu Z; Ding P; Li L; Lin J; Catteau A; Galon J; Chen G
Oncoimmunology; 2023; 12(1):2161167. PubMed ID: 36632564
[TBL] [Abstract][Full Text] [Related]
39. Inclusion of BLIMP-1
Ward-Hartstonge KA; McCall JL; McCulloch TR; Kamps AK; Girardin A; Cretney E; Munro FM; Kemp RA
Cancer Immunol Immunother; 2017 Apr; 66(4):515-522. PubMed ID: 28116480
[TBL] [Abstract][Full Text] [Related]
40. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
